<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000771</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 192</org_study_id>
    <secondary_id>11167</secondary_id>
    <nct_id>NCT00000771</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the effectiveness of oral paromomycin sulfate for 21 days compared to placebo in&#xD;
      the treatment of cryptosporidiosis in patients with HIV infection. To evaluate the safety of&#xD;
      oral paromomycin at two different doses. To explore whether paromomycin administered over a&#xD;
      longer period provides additional benefit.&#xD;
&#xD;
      In previous studies, patients with cryptosporidiosis demonstrated dramatic improvement with&#xD;
      paromomycin therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In previous studies, patients with cryptosporidiosis demonstrated dramatic improvement with&#xD;
      paromomycin therapy.&#xD;
&#xD;
      Patients are randomized to receive either placebo or paromomycin for 3 weeks. After the&#xD;
      initial double-blind phase, all patients receive open-label paromomycin for 3 weeks.&#xD;
      Following 6 weeks of therapy, patients who do not achieve a complete response receive a&#xD;
      higher dose of paromomycin for an additional 3 weeks, while complete responders continue&#xD;
      receiving the original dose for an additional 3 weeks. Complete or partial responders after 9&#xD;
      weeks may receive 16 additional weeks of optional maintenance therapy at the dose at which&#xD;
      their response was achieved. Treatment continues for up to 25 weeks total. Patients are&#xD;
      followed at weeks 1, 3, 4, 6, 7, and 9, and then at 2-4 week intervals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>68</enrollment>
  <condition>Cryptosporidiosis</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Macrolides for disseminated Mycobacterium avium.&#xD;
&#xD;
          -  Atovaquone for toxoplasmosis.&#xD;
&#xD;
          -  Other antimicrobials for concurrent infections.&#xD;
&#xD;
          -  Lomotil, Imodium, or deodorized opium tincture in a standardized regimen for diarrhea.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Advanced HIV disease.&#xD;
&#xD;
          -  Diarrhea presumptively caused by Cryptosporidia.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Hypersensitivity to aminoglycosides.&#xD;
&#xD;
          -  Inability to swallow capsules.&#xD;
&#xD;
          -  Active infection due to other enteric pathogens. Previous diagnosis of CMV or MAC&#xD;
             infection permitted if patient is currently stabilized on a therapeutic regimen&#xD;
             (clarithromycin up to 500 mg bid or azithromycin up to 600 mg daily).&#xD;
&#xD;
          -  Other known causes for diarrhea (e.g., malabsorption syndrome, gastrointestinal&#xD;
             Kaposi's sarcoma).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded during the first 9 weeks of study:&#xD;
&#xD;
          -  Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril,&#xD;
             letrazuril, or bovine colostrum).&#xD;
&#xD;
          -  Octreotide acetate (Sandostatin).&#xD;
&#xD;
          -  Antidiarrheals other than those specifically allowed.&#xD;
&#xD;
          -  Clarithromycin if initiated at 500 mg or higher or azithromycin if initiated at 600 mg&#xD;
             or higher.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Paromomycin at &gt; 1 g/day for &gt;= 14 days prior to study entry.&#xD;
&#xD;
        Excluded within 14 days prior to study entry:&#xD;
&#xD;
          -  Agents with putative anticryptosporidial activity (such as spiramycin, diclazuril,&#xD;
             letrazuril, or bovine colostrum), with the exception of macrolides that are permitted&#xD;
             for other indications.&#xD;
&#xD;
          -  Octreotide acetate (Sandostatin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carey J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weiss Memorial Hosp.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp. of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University A2201</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hewitt RG, Yiannoutsos CT, Higgs ES, Carey JT, Geiseler PJ, Soave R, Rosenberg R, Vazquez GJ, Wheat LJ, Fass RJ, Antoninievic Z, Walawander AL, Flanigan TP, Bender JF. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis. 2000 Oct;31(4):1084-92. doi: 10.1086/318155. Epub 2000 Oct 25.</citation>
    <PMID>11049793</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryptosporidiosis</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Paromomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryptosporidiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

